F
COMPANY PROFILE
Formycon
Formycon is an independent developer of high-quality biosimilars with focus on treatments in ophthalmology, immunology and other key chronic diseases
Valuation
$367M
Market cap · 2026
Revenue
$80M
Latest reported FY
At a glance
- Status
- Listed
- Founded
- 1999
- Headquarters
- Planegg, Germany
- Listing
- IPO 2010
- Sector
- Biotech & Life Sciences
- Power Law
- Colt$25–100M revenue
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
Gedeon Richter
Team profiled
3
named & role-tagged
Founders
Hidden — book a demo/100
quality score
Key operators
Hidden — book a demo
quality score
Potential founders
Hidden — book a demo
likely future founders
Startup mafia
Hidden — book a demo
alumni-founded startups
Talent movements
Hidden — book a demo in · Hidden — book a demo out
past 12 months
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Formycon on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Formycon on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.